Skip to Content
Merck
All Photos(2)

Key Documents

More Documents

I4161

Sigma-Aldrich

Interleukin-2 from mouse

IL-2, recombinant, expressed in E. coli, carrier free

Synonym(s):

mIL-2, IL-2, T-cell growth factor

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

MDL number:
MFCD00164816
UNSPSC Code:
12352202
NACRES:
NA.77

biological source

mouse

Quality Level

200

recombinant

expressed in E. coli

Assay

≥97% (SDS-PAGE)

form

lyophilized powder

potency

≤0.2 ng/mL ED50

quality

endotoxin tested

mol wt

17.2 kDa

packaging

pkg of 5X20 μg
pkg of 20 μg

technique(s)

cell culture | mammalian: suitable

impurities

≤0.200ng/ml

color

white

UniProt accession no.

P04351

shipped in

dry ice

storage temp.

−20°C

Gene Information

mouse ... Il2(16183)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

Interleukin-2 (IL-2) is a powerful immunoregulatory lymphokine produced by T-cells in response to antigenic or mitogenic stimulation. Recombinant human IL-2 is a 15.5 kDa protein, containing 134 amino acid residues including one intrachain disulfide bond.

Physical form

Lyophilized with no additives.

Reconstitution

Centrifuge vial prior to opening. Reconstitute the contents of the vial in water to a concentration range of 0.1-1.0 mg/mL.
IL-2 is a powerful immunoregulatory lymphokine produced by T-cells in response to antigenic or mitogenic stimulation. IL-2/IL-2R signaling is required for T-cell proliferation and other fundamental functions which are essential for the immune response. IL-2 stimulates growth and differentiation of B-cells, NK cells, lymphokine activated killer cells, monocytes, macrophages and oligodendrocytes. Recombinant human IL-2 is a 15.5 kDa protein, containing 134 amino acid residues including one intrachain disulfide bond.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H319 - H335

Hazard Classifications

Eye Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

10 - Combustible liquids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Joaquin De Haro et al.
Journal of vascular surgery, 62(6), 1625-1631 (2014-07-22)
This study assessed the effect of cellular and humoral autoimmune response inhibition after immunization with β2-glycoprotein I (β2-GPI) and the effect of immunomodulation with interleukin (IL)-2 and IL-10 in the development of early atherosclerotic vascular lesion in a murine model.
Nabil Ahmed et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33(15), 1688-1696 (2015-03-25)
The outcome for patients with metastatic or recurrent sarcoma remains poor. Adoptive therapy with tumor-directed T cells is an attractive therapeutic option but has never been evaluated in sarcoma. We conducted a phase I/II clinical study in which patients with
Fang-Ting Lu et al.
Journal of autoimmunity, 61, 62-72 (2015-06-15)
Thymic CD4(+) FoxP3(+) regulatory T (Treg) cells are critical for the development of immunological tolerance and immune homeostasis and requires contributions of both thymic dendritic and epithelial cells. Although B cells have been reported to be present within the thymus
Sushama Telwatte et al.
Nucleic acids research, 43(6), 3256-3271 (2015-03-15)
Resistance to combined antiretroviral therapy (cART) in HIV-1-infected individuals is typically due to nonsynonymous mutations that change the protein sequence; however, the selection of synonymous or 'silent' mutations in the HIV-1 genome with cART has been reported. These silent K65K
Haiying Qin et al.
Blood, 126(5), 629-639 (2015-06-05)
Adoptive transfer of T cells genetically modified to express chimeric antigen receptors (CARs) targeting the CD19 B cell-associated protein have demonstrated potent activity against relapsed/refractory B-lineage acute lymphoblastic leukemia (B-ALL). Not all patients respond, and CD19-negative relapses have been observed.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service